Woodworth, Kate R;
Moulia, Danielle;
Collins, Jennifer P;
Hadler, Stephen C;
Jones, Jefferson M;
Reddy, Sujan C;
Chamberland, Mary;
Campos-Outcalt, Doug;
Morgan, Rebecca L;
Brooks, Oliver;
Talbot, H. Keipp;
Lee, Grace M;
Bell, Beth P;
Daley, Matthew F;
Mbaeyi, Sarah;
Dooling, Kathleen;
Oliver, Sara E.
The Pfizer-BioNTech COVID-19 (BNT162b2) vaccine is a lipid nanoparticle–formulated, nucleoside-modified mRNA vaccine encoding the prefusion spike glycoprotein of SARS-CoV-2, the virus that causes COVID-19. On August 23, 2021, the Food and Drug Administration (FDA) approved a Biologics License Applicati...
Estimated rates of influenza-associated hospitalization and death are generally highest among individuals 65 years of age and older (1-4), an age group for whom influenza vaccine effectiveness is often lower relative to younger populations (5, 6). Two inactivated influenza vaccines approved in the U.S. f...
Wallace, Megan;
Moulia, Danielle;
Blain, Amy E;
Ricketts, Erin K;
Minhaj, Faisal S;
Link-Gelles, Ruth;
Curran, Kathryn G;
Hadler, Stephen C;
!Asif, Amimah;
Godfrey, Monica;
Hall, Elisha;
Fiore, Anthony;
Meyer, Sarah;
Su, John R;
Weintraub, Eric;
Oster, Matthew E;
Shimabukuro, Tom T;
Campos-Outcalt, Doug;
Morgan, Rebecca L;
Bell, Beth P;
Brooks, Oliver;
Talbot, H. Keipp;
Lee, Grace M;
Daley, Matthew F;
Oliver, Sara E.
The mRNA-1273 (Moderna) COVID-19 vaccine is a lipid nanoparticle-encapsulated, nucleoside-modified mRNA vaccine encoding the stabilized prefusion spike glycoprotein of SARS-CoV-2, the virus that causes COVID-19. During December 2020, the vaccine was granted Emergency Use Authorization (EUA) by the Food a...
Oliver, Sara E;
Wallace, Megan;
See, Isaac;
Mbaeyi, Sarah;
Godfrey, Monica;
Hadler, Stephen C;
Jatlaoui, Tara C;
Twentyman, Evelyn;
Hughes, Michelle M;
Rao, Agam K;
Fiore, Anthony;
Su, John R;
Broder, Karen R;
Shimabukuro, Tom;
Lale, Allison;
Shay, David K;
Markowitz, Lauri E;
Wharton, Melinda;
Bell, Beth P;
Brooks, Oliver;
McNally, Veronica;
Lee, Grace M;
Talbot, H. Keipp;
Daley, Matthew F.
On February 27, 2021, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the adenovirus-vectored COVID-19 vaccine (Janssen Biotech, Inc., a Janssen Pharmaceutical company, Johnson & Johnson), and on February 28, 2021, the Advisory Committee on Immunization Practices (A...
